• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Nirsevimab

Nirsevimab (MEDI8897) 是一种具有修饰 Fc 区的重组人呼吸道合胞病毒 (RSV) 单克隆抗体。Nirsevimab 高效靶向 RSV-B ，Kd 值为 1.5 nM。Nirsevimab 可用于预防 RSV 感染。

CAS号

1989556-22-0

分子式

主要靶点

RSV

仅限科研使用

Cat No : CM17450

Print datasheet

Synonyms

MEDI8897

验证数据展示

  • CAS No.: 1989556-22-0

    Nirsevimab
    CAS#: 1989556-22-0

产品信息

Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region. Nirsevimab efficiently targets RSV-B with a Kd value of 1.5 nM. Nirsevimab can be used to prevent RSV infection.

CAS号 1989556-22-0
分子式
主要靶点 RSV
主要通路 微生物学
分子量
纯度 ， 此纯度可做参考，具体纯度与批次有关系，可咨询客服
储存条件
别名 MEDI8897

参考文献

1.Griffin MP, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425.
2.Griffin MP, et al. Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e01714-16.
3.Cabán M, et al. Cross-protective antibodies against common endemic respiratory viruses. Nat Commun. 2023 Feb 13;14(1):798.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2